Adagrasib safe and clinically active in non-small cell lung cancer
- 5 August 2022
- conference paper
- conference paper
- Published by Medicom Medische Uitgeverij BV in Medicom Conference Report ASCO 2022
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Adagrasib in Non–Small-Cell Lung Cancer Harboring a
KRAS
G12C
MutationThe New England Journal of Medicine, 2022
- KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation.Journal of Clinical Oncology, 2022
- LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutationAnnals of Oncology, 2021